Thomas Waldmann, M.D.
Metabolism Branch
Head, Cytokine Immunology and Immunotherapy Section
Branch Chief
National Cancer Institute
9000 Rockville Pike
Building 10, Room 4N115
Bethesda, MD 20892
Phone: 301-496-6656
Fax: 301-496-9956
tawald@helix.nih.gov
Dr. Waldmann received his M.D. from Harvard Medical School. He joined NCI in 1956 and has been chief of the Metabolism Branch since 1973. He studies the IL-2/IL-2 receptor system in growth of normal and neoplastic cells. He co-discovered IL-15 and introduced various forms of IL-2/IL-15R-directed therapy for leukemia and autoimmune diseases. He has initiated clinical trials employing this cytokine in the treatment of metastatic malignancy. His honors include the Ehrlich medal; the Stratton, Lila Gruber, Simon Shubitz, Milken, Artois-Baillet Latour, and Bristol-Myers Squibb prizes; AAI-Dana Foundation Award in Human Immunology Research; and election to the National Academy of Sciences, American Academy of Arts and Sciences, and Institute of Medicine, NAS.
Dr. Waldmann's Clinical Trial(s):
NCI's Center for Cancer Research (CCR) is currently conducting the following trial(s) for patients with leukemia, lymphoma, melanoma, and kidney cancer. Click on the trial(s) below for additional details, including a summary of primary eligibility, study outline, and information on how to contact the study team directly.
Back to Top
